Tibet Rhodiola Pharmaceutical Holding Co (SHG:600211) — Market Cap & Net Worth
Market Cap & Net Worth: Tibet Rhodiola Pharmaceutical Holding Co (600211)
Tibet Rhodiola Pharmaceutical Holding Co (SHG:600211) has a market capitalization of $1.96 Billion (CN¥13.38 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #6402 globally and #1444 in its home market, demonstrating a 1.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tibet Rhodiola Pharmaceutical Holding Co's stock price CN¥41.50 by its total outstanding shares 322319196 (322.32 Million). Analyse 600211 cash generation efficiency to see how efficiently the company converts income to cash.
Tibet Rhodiola Pharmaceutical Holding Co Market Cap History: 2015 to 2026
Tibet Rhodiola Pharmaceutical Holding Co's market capitalization history from 2015 to 2026. Data shows growth from $1.33 Billion to $1.96 Billion (5.35% CAGR).
Tibet Rhodiola Pharmaceutical Holding Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tibet Rhodiola Pharmaceutical Holding Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.62x
Tibet Rhodiola Pharmaceutical Holding Co's market cap is 0.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.66x
Tibet Rhodiola Pharmaceutical Holding Co's market cap is 1.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.33 Billion | $1.38 Billion | $91.64 Million | 0.96x | 14.54x |
| 2016 | $1.65 Billion | $796.81 Million | $198.29 Million | 2.08x | 8.35x |
| 2017 | $1.03 Billion | $915.63 Million | $229.65 Million | 1.13x | 4.50x |
| 2018 | $917.23 Million | $1.03 Billion | $215.61 Million | 0.89x | 4.25x |
| 2019 | $1.00 Billion | $1.26 Billion | $312.32 Million | 0.80x | 3.22x |
| 2020 | $3.08 Billion | $1.37 Billion | $418.10 Million | 2.24x | 7.36x |
| 2021 | $2.42 Billion | $2.14 Billion | $208.94 Million | 1.13x | 11.58x |
| 2022 | $1.67 Billion | $2.55 Billion | $369.84 Million | 0.66x | 4.53x |
| 2023 | $2.30 Billion | $3.13 Billion | $800.91 Million | 0.73x | 2.87x |
| 2024 | $1.74 Billion | $2.81 Billion | $1.05 Billion | 0.62x | 1.66x |
Competitor Companies of 600211 by Market Capitalization
Companies near Tibet Rhodiola Pharmaceutical Holding Co in the global market cap rankings as of May 7, 2026.
Key companies related to Tibet Rhodiola Pharmaceutical Holding Co by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #501 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #530 globally with a market cap of $50.06 Billion USD ( CN¥342.11 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #541 globally with a market cap of $49.01 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #574 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #501 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.06 Billion | CN¥53.63 |
| #541 | Zoetis Inc | NYSE:ZTS | $49.01 Billion | $111.22 |
| #574 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $43.83 |
Tibet Rhodiola Pharmaceutical Holding Co Historical Marketcap From 2015 to 2026
Between 2015 and today, Tibet Rhodiola Pharmaceutical Holding Co's market cap moved from $1.33 Billion to $ 1.96 Billion, with a yearly change of 5.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.96 Billion | -2.47% |
| 2025 | CN¥2.01 Billion | +15.19% |
| 2024 | CN¥1.74 Billion | -24.30% |
| 2023 | CN¥2.30 Billion | +37.46% |
| 2022 | CN¥1.67 Billion | -30.77% |
| 2021 | CN¥2.42 Billion | -21.35% |
| 2020 | CN¥3.08 Billion | +206.24% |
| 2019 | CN¥1.00 Billion | +9.48% |
| 2018 | CN¥917.23 Million | -11.28% |
| 2017 | CN¥1.03 Billion | -37.53% |
| 2016 | CN¥1.65 Billion | +24.21% |
| 2015 | CN¥1.33 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Tibet Rhodiola Pharmaceutical Holding Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.96 Billion USD |
| MoneyControl | $1.96 Billion USD |
| MarketWatch | $1.96 Billion USD |
| marketcap.company | $1.96 Billion USD |
| Reuters | $1.96 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. manufactures pharmaceuticals in China and internationally. The company offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. It also provides capsules, biological preparations, granules, and film-coating agents for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthr… Read more